- Ring The Bell
- Posts
- ⏰ Why Peter Schiff Is Sounding The Alarm On The Economy
⏰ Why Peter Schiff Is Sounding The Alarm On The Economy
Plus, uncover enticing ideas abroad, and more
You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.
Happy Wednesday! Despite the S&P 500’s rally, Peter Schiff argues that inflation distorts its true value, with gold significantly outperforming stocks over the past two decades. Here’s why Schiff sees trouble ahead — and how investors can position themselves in response. Also, discover undervalued global stocks that deserve your attention.
—Josh Enomoto
Plus, if you’re interested in an innovative approach to medicine, check out today’s sponsor.
MARKET RECAP
Last week: Stocks closed little changed Tuesday, with the S&P 500 edging up 0.2% while the Dow and Nasdaq hovered near the flatline. Energy and materials stocks led gains, fueled by a spike in oil prices, while bond yields climbed as the 10-year Treasury yield hit 4.55%. Investors remain focused on corporate earnings strength and broader economic conditions as markets navigate ongoing uncertainties.
On Our Radar: After digesting housing starts and building permits data, economists will next turn to Thursday’s initial jobless claims. On the earnings front, email marketing platform Klaviyo will release its results after the closing bell today.
TOP STORY
Peter Schiff warns that the stock market’s gains are an illusion when measured against gold, which has surged nearly 1,000% since 2000.
SPONSORED CONTENT
Kamada Ltd. (NASDAQ: KMDA) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases with limited treatment alternatives.
Kamada’s vertically integrated model aims to ensure control over plasma collection, manufacturing and commercialization, reducing supply chain risks while enhancing efficiency.
With six FDA-approved products, the company continues to expand through organic growth, strategic M&A and increased plasma collection capacity. Kamada says its commitment to innovation and operational excellence positions it for long-term growth in a rapidly evolving industry. As demand for specialized treatments rises, Kamada remains a company to watch for those seeking exposure to the future of biopharmaceuticals. Learn more about the company here.
This is a paid ad. Please see 17b disclosure here for more information.
FIVE ZINGERS
Record High: Tech stocks continued to pour on the momentum, with the Nasdaq-100 surging to a fresh record. Read about the individual names leading the charge.
First Look: A well-known Apple product leak source shared renderings of the upcoming iPhone 17 Air and iPhone 17 Pro. Discover the attributes setting these successor models apart from the competition.
Tough Miss: Toll Brothers disclosed its fiscal Q1 results, which fell short of top and bottom-line targets. Learn about what sparked the disappointing results.
Big Boost: Devon Energy disclosed its fiscal Q4 results after the bell on Tuesday, revealing better-than-expected production. Here are the other catalysts that got investors excited.
Smart Move: Starbucks eschewed airing a Super Bowl commercial and instead opted for a day-after promotion. See why the move could pay dividends.
SPECIAL OFFER
Editor’s Note: Every Tuesday, Benzinga Edge members receive the Under the Radar pick, detailing a very profitable stock or market trend that no one’s talking about. Here’s a sneak peek at yesterday’s:
Today, I decided to look at stocks that passed all the filters. I screened for companies that passed the Magic Formula Filters of high earning yields and high returns of capital. Then, I filtered out those with low profitability levels and Piotroski F-scores.
This produced a list of profitable companies with strong finances that are currently undervalued. I immediately noticed that the best bargains were outside the United States. This is unsurprising, given the huge performance gap over the past several years.
While running the numbers, I made a surprise discovery.
Buying high-quality, undervalued U.S. companies has beaten the markets even during the past five tech-dominated years.
Companies outside the U.S. (excluding China) have done even better.
Given that there are far more bargain opportunities outside the United States than inside, there is a good chance that this outperformance will continue.
Get all the details from yesterday’s Benzinga Edge-exclusive Under the Radar report. Click here to get a sneak peek.
SPECIAL OFFER
When Walmart reports earnings tomorrow, the ripple effects could shake the entire market. Our Earnings Command Center gives you real-time alerts, key data and actionable insights—before the news breaks. Click here to get your earnings edge now.
BEFORE YOU GO
Were you forwarded this email? Click here to subscribe.
And be sure to check out our other newsletters:
Future Finance: Where fintech, crypto and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.
Cannabis Daily: A must-read daily briefing for cannabis investors, operators and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.
Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis and news. Subscribe here.
Tech Trends: Get the inside scoop on AI, the hottest gadgets and mind-blowing tech trends. Subscribe here.